Comparing Intra-Cellular Therapies (ITCI) and Its Competitors
Intra-Cellular Therapies (NASDAQ: ITCI) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Intra-Cellular Therapies to similar businesses based on the strength of its dividends, earnings, risk, profitability, valuation, institutional ownership and analyst recommendations.
Risk and Volatility
Intra-Cellular Therapies has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies’ peers have a beta of 6.66, indicating that their average share price is 566% more volatile than the S&P 500.
This is a breakdown of current recommendations for Intra-Cellular Therapies and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Intra-Cellular Therapies Competitors||761||3027||11175||227||2.72|
Intra-Cellular Therapies currently has a consensus price target of $26.14, suggesting a potential upside of 64.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.53%. Given Intra-Cellular Therapies’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Intra-Cellular Therapies is more favorable than its peers.
Insider and Institutional Ownership
59.4% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.0% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Intra-Cellular Therapies and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Intra-Cellular Therapies||$312,285.00||-$104.39 million||-6.70|
|Intra-Cellular Therapies Competitors||$260.16 million||$66.28 million||-6.61|
Intra-Cellular Therapies’ peers have higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Intra-Cellular Therapies and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intra-Cellular Therapies Competitors||-5,511.45%||-449.45%||-42.34%|
Intra-Cellular Therapies beats its peers on 7 of the 12 factors compared.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company’s bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer’s Disease (AD).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.